IRIS
DEL MASTRO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.176
AS - Asia 4.777
NA - Nord America 4.445
Continente sconosciuto - Info sul continente non disponibili 1.205
SA - Sud America 400
AF - Africa 117
OC - Oceania 16
Totale 40.136
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.067
US - Stati Uniti d'America 4.145
SG - Singapore 1.734
CN - Cina 1.122
BD - Bangladesh 713
VN - Vietnam 706
FR - Francia 334
FI - Finlandia 276
BR - Brasile 235
HK - Hong Kong 193
DE - Germania 131
CA - Canada 114
NL - Olanda 88
GB - Regno Unito 71
AR - Argentina 68
JP - Giappone 59
ES - Italia 54
MX - Messico 50
IN - India 40
ID - Indonesia 28
IQ - Iraq 27
JM - Giamaica 27
RU - Federazione Russa 26
CH - Svizzera 25
EC - Ecuador 25
CO - Colombia 23
MW - Malawi 23
PH - Filippine 21
CL - Cile 18
ZA - Sudafrica 18
AU - Australia 16
HN - Honduras 16
SV - El Salvador 16
CR - Costa Rica 15
EG - Egitto 14
GT - Guatemala 14
MY - Malesia 14
SA - Arabia Saudita 14
TR - Turchia 14
AT - Austria 13
IE - Irlanda 13
BE - Belgio 12
MA - Marocco 12
DZ - Algeria 11
KE - Kenya 11
PK - Pakistan 11
TH - Thailandia 11
PY - Paraguay 10
SE - Svezia 10
VE - Venezuela 10
NI - Nicaragua 9
TT - Trinidad e Tobago 9
PR - Porto Rico 8
UA - Ucraina 8
UZ - Uzbekistan 8
KR - Corea 7
LB - Libano 7
PL - Polonia 7
RO - Romania 7
TW - Taiwan 7
NP - Nepal 6
BS - Bahamas 5
RS - Serbia 5
BB - Barbados 4
DO - Repubblica Dominicana 4
JO - Giordania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CG - Congo 3
CI - Costa d'Avorio 3
IL - Israele 3
IR - Iran 3
KW - Kuwait 3
KZ - Kazakistan 3
PE - Perù 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
CU - Cuba 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
HR - Croazia 2
KH - Cambogia 2
LT - Lituania 2
LY - Libia 2
NO - Norvegia 2
OM - Oman 2
SI - Slovenia 2
VI - Stati Uniti Isole Vergini 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
Totale 38.905
Salva come PNG Salva come JPEG
Città #
Genova 12.582
Genoa 9.897
Rapallo 2.503
Vado Ligure 2.270
San Jose 864
Singapore 841
Ashburn 599
Council Bluffs 284
Lauterbourg 284
Helsinki 256
Ho Chi Minh City 210
New York 203
Beijing 190
Hong Kong 175
Hanoi 154
Santa Clara 138
Bordighera 95
Los Angeles 91
Frankfurt am Main 89
Boardman 83
Milan 73
Buffalo 54
Tokyo 52
Rome 49
Chicago 47
Amsterdam 46
Naples 41
Dallas 35
Haiphong 33
Da Nang 29
Mexico City 29
São Paulo 29
Boston 27
Orem 27
Phoenix 25
Bologna 24
Houston 23
Atlanta 22
Tianjin 22
Bar Harbor 20
Kingston 20
Miami 20
Madrid 19
Philadelphia 19
Lappeenranta 18
Toronto 18
Charlotte 17
Zurich 17
Guangzhou 15
Barcelona 14
Brooklyn 14
Hải Dương 14
Montreal 14
San Salvador 14
St Louis 14
Bari 13
Dublin 13
Palermo 13
San Antonio 13
Schiffdorf 13
City of London 12
Curitiba 12
Des Moines 12
Houten 12
Orlando 12
Phủ Lý 12
San José 12
Shenzhen 12
Turin 12
Brescia 11
Columbus 11
Las Vegas 11
Seattle 11
Baghdad 10
Cleveland 10
Enfield 10
Guatemala City 10
Melbourne 10
Minneapolis 10
Newark 10
Piscataway 10
Quito 10
Shanghai 10
Surrey 10
Venice 10
Verona 10
Washington 10
Biên Hòa 9
Cincinnati 9
Denver 9
Detroit 9
Florence 9
Huntsville 9
Managua 9
Paris 9
Queens 9
Santiago 9
The Bronx 9
Catania 8
Fort Lauderdale 8
Totale 33.234
Salva come PNG Salva come JPEG
Nome #
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† 443
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 309
Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. 249
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 247
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 241
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 227
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs) 226
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 208
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 208
Cancer and fertility preservation: international recommendations from an expert meeting 206
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies 205
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature 197
Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies 197
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study 196
Management of young women with early breast cancer 192
Circulating tumor DNA using tagged targeted deep sequencing to assess minimal residual disease in breast cancer patients undergoing neoadjuvant chemotherapy 190
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence 189
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 189
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial 187
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate? 186
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials 185
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer 185
Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients 183
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 182
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 182
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 181
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 181
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients 179
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 179
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 179
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 177
A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes 172
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey 172
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 171
Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence 171
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 171
Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes 171
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 169
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 168
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 168
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial 168
News on the medical treatment of young women with early-stage HER2-negative breast cancer 167
Treatment with aromatase inhibitors and markers of cardiovascular disease 166
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 166
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 165
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 165
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 165
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 165
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity 164
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial 163
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 163
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer 163
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients 162
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 162
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 161
Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology 161
Gender minorities in breast cancer - Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 160
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 160
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial 160
Taxane-containing chemotherapy in the treatment of early breast cancer patients 160
Pharmacotherapy to protect ovarian function and fertility during cancer treatment 160
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 160
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 158
Optimization of a wga-free molecular tagging-based ngs protocol for ctcs mutational profiling 158
Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system’s inhibitor denosumab vs. bisphosphonates 157
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence 157
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 157
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole 157
A case where switching end points for clinical trial interpretation might be the right choice 156
Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer 155
Exploring the safety of chemotherapy for treating breast cancer during pregnancy 155
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group 154
Targeting bone metastatic cancer: Role of the mTOR pathway 154
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. 154
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 153
Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? 151
Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives 151
Letrozole withdrawal response in locally advanced breast cancer 151
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 151
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells 151
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 150
Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors 150
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 150
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy 150
Anthracycline-free therapy for HER2-amplified breast cancer 149
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer 149
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 148
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 148
Predicting mood disorders in breast cancer patients. 148
Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies 148
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations 148
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 148
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis 146
Fertility, sexuality and cancer in young adult women 146
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 144
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study 144
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy 143
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 143
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 142
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 141
Totale 17.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 139.416
article - articoli 139.146
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 270
Totale 278.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.704 142 108 128 261 73 302 97 616 279 247 96 355
2022/20233.079 274 249 31 283 448 457 79 379 507 27 305 40
2023/20241.831 72 227 55 250 145 191 127 154 80 106 110 314
2024/20255.998 194 442 159 382 725 711 494 956 295 340 594 706
2025/202614.648 1.232 517 1.623 1.154 1.594 1.017 1.997 710 1.029 1.450 1.014 1.311
2026/20271.270 1.270 0 0 0 0 0 0 0 0 0 0 0
Totale 40.136